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1 | INTRODUCTION
This expert consensus statement of the European Heart Rhythm Asso-
ciation (EHRA), Heart Rhythm Society (HRS), Asia Pacific Heart
Rhythm Society (APHRS), and the Latin American Heart Rhythm Soci-
ety (LAHRS) summarizes the consensus of the international writing
group and is based on a thorough review of the medical literature
regarding cognitive function in arrhythmias. The document is intended
to describe the impact of different types of arrhythmias on cognitive
function, to highlight possible risk markers for cognitive decline and to
formulate implications for clinical practice regarding follow-up meth-
ods, prevention and treatment strategies. Our objective is to raise
awareness of cognitive function among physicians treating patients
with arrhythmias and to provide them with practical proposals that
may lead to improvement of patient care in this regard.
This document reviews terminology and the epidemiology of
cognitive dysfunction, methods for assessment of cognitive function
and the role of imaging. Recent studies have suggested possible
associations between cognitive decline and atrial fibrillation (AF). We
review the reported literature on AF and cognitive function, includ-
ing the scenarios of AF with overt stroke, silent stroke, or no stroke,
and then make recommendations for assessment of cognitive func-
tion and prevention of cognitive decline in patients with AF in clini-
cal practice. The document also reviews the association of other
arrhythmias and cognitive dysfunction, including settings such as
post-cardiac arrest, cardiac implantable devices, such as implantable
cardioverter-defibrillators (ICDs) and pacemakers, or ablation proce-
dures. Implications for electrophysiological procedures and cognitive
function are discussed. Long QT syndrome and cognitive function is
not addressed in the document. For quick reference, sub-chapters
are followed by a short section on consensus recommendations. The
document concludes with a summary of consensus statements, cur-
rent knowledge gaps, and future directions of research.
1.1 | Evidence review
Members of the Task Force were asked to perform a detailed litera-
ture review, weigh the strength of evidence for or against a
particular treatment or procedure, and include estimates of expected
health outcomes for which data exist. Patient-specific modifiers, co-
morbidities, and issues of patient preference that might influence
the choice of particular tests or therapies are considered, as are fre-
quency of follow-up and cost-effectiveness. In controversial areas, or
with regard to issues without evidence other than usual clinical prac-
tice, a consensus was achieved by agreement of the expert panel
after thorough deliberations. This document was prepared by the
Task Force with representation from EHRA, HRS, APHRS, and
LAHRS. The document was peer-reviewed by official external
reviewers representing EHRA, HRS, APHRS, and LAHRS.
Consensus statements are evidence-based and derived primarily
from published data or determined through consensus opinion if
data are not available. Current systems of ranking level of evidence
are becoming complicated in a way that their practical utility might
be compromised.1 In contrast to guidelines, we opted for an easier
and user-friendly system of ranking using “coloured hearts” that
should allow physicians to easily assess the current status of the evi-
dence and consequent guidance (Table 1). This EHRA grading of
consensus statements does not have separate definitions of the level
of evidence. This categorization, used for consensus statements,
must not be considered as directly similar to that used for official
society guideline recommendations, which apply a classification
(Class I-III) and level of evidence (A, B, and C) to recommendations
used in official guidelines.
Thus, a green heart indicates a “should do this” consensus state-
ment or indicated treatment or procedure that is based on at least
one randomized trial, or is supported by strong observational evi-
dence that it is beneficial and effective. A yellow heart indicates
general agreement and/or scientific evidence favouring a “may do
this” statement or the usefulness/efficacy of a treatment or proce-
dure. A “yellow heart” symbol may be supported by randomized tri-
als based on a small number of patients or which is not widely
applicable. Treatment strategies for which there is scientific evidence
of potential harm and should not be used (“do not do this”) are indi-
cated by a red heart.
Finally, this is a consensus document that includes evidence and
expert opinions from several countries. The pharmacological and
TABLE 1 Scientific rationale of recommendationsa
Definitions related to a treatment or procedure Consensus statement instruction Symbol
Scientific evidence that a treatment or procedure is beneficial and effective. Requires at least one
randomized trial, or is supported by strong observational evidence and authors’ consensus (as
indicated by an asterisk)
“Should do this”
General agreement and/or scientific evidence favour the usefulness/efficacy of a treatment or
procedure. May be supported by randomized trials based on a small number of patients or which
is not widely applicable
“May do this”
Scientific evidence or general agreement not to use or recommend a treatment or procedure “Do not do this”
aThis categorization for our consensus document should not be considered as being directly similar to that used for official society guideline recommen-
dations which apply a classification (I-III) and level of evidence (A, B, and C) to recommendations.
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non-pharmacological antiarrhythmic approaches discussed may,
therefore, include drugs that do not have the approval of govern-
mental regulatory agencies in all countries.
1.2 | Relationships with industry and other conflicts
All members of the writing group, as well as reviewers, have dis-
closed any potential conflict of interest in detail and is available in
Appendix S1-S3.
All recommendations were voted upon by the writing committee
independently and reached ≥80% consensus for inclusion in recom-
mendations tables. Each partner society officially reviewed the
document and all reviewer comments were addressed. The final
document and recommendations were approved by each partner
society.
2 | DECLINE OF COGNITIVE FUNCTION:
TERMINOLOGY AND EPIDEMIOLOGY
2.1 | Terminology: cognitive decline, mild cognitive
impairment, and dementia
Cognitive decline that is greater than expected from normal aging
can be ascertained from changes in standardized cognitive test
scores over time. Examples of standardized cognitive tests that eval-
uate different cognitive domains include Delayed Word Recall test
(short-term memory),2 Digit Symbol Substitution test (executive
function and processing speed),3 and Word Fluency test (executive
function and expressive language).4
Mild cognitive impairment is an intermediate stage between the
expected cognitive decline of normal aging and the more serious
abnormality of dementia. Mild cognitive impairment is characterized
by declines in cognitive function and objective long-term cognitive
deficit that does not affect activities of daily living.5
Dementia is defined as deficits in ≥2 cognitive domains that rep-
resent a decline from previous level of functioning and that are suffi-
ciently severe to affect activities of daily living. Both mild cognitive
impairment and dementia can be further classified into subtypes.6
Mild cognitive impairment can be sub-typed into four groups (based
on the scheme adopted by the National Institute on Aging Alzhei-
mer’s Disease Centers Program for the Uniform Data Set) as amnes-
tic or non-amnestic, single or multiple domain.5 Dementia can be
classified into aetiologic diagnoses: Alzheimer’s disease, vascular
dementia, Lewy body dementia, frontotemporal dementia, and other
dementias.6
2.2 | Epidemiology of dementia
A recent systematic review provided some insights into the contem-
porary (1980-2009) prevalence of dementia in individuals aged
≥60 years in 21 Global Burden of Disease regions: age-standardized
prevalence for those aged ≥60 years varied in a narrow band (5-7%
in most world regions), with a higher prevalence in Latin America
(8.5%), and a lower prevalence in the four sub-Saharan African
regions (2-4%).7 Approximately 35.6 million people lived with
dementia worldwide in 2010, with numbers expected to almost dou-
ble every 20 years, to 65.7 million in 2030 and 115.4 million in
2050.7 In 2010, 58% of all people with dementia lived in countries
with low or middle incomes, with this proportion anticipated to rise
to 63% in 2030 and 71% in 2050.7 Thus, dementia is a burgeoning
global public health problem that prompts an urgent and more com-
prehensive understanding of its risk factors with the aim to discover
novel prevention strategies.
The burden of dementia is rapidly increasing owing to the aging
of the population. Other than advancing age, risk factors for demen-
tia, particularly vascular dementia, have been extensively studied
from an epidemiological perspective. Broadly, they can be classified
as dementia due to non-modifiable risk factors, lifestyle factors,
physiological risk factors, or clinical cardiovascular or cerebrovascular
disease. Selected risk factors are shown in Table 2 and include many
of the risk factors included in stroke risk scores in AF.
3 | METHODS FOR ASSESSMENT OF
COGNITIVE FUNCTION
Impairments of cognitive function often can be subtle and insidious,
presenting as missed appointments, mislaying objects, or minor prob-
lems at work or home, which are often attributed to stress, age, or
pressure of work. Any difference in appearance, behaviour or func-
tioning reported by the patient or the family should alert the physi-
cian to the need for a formal assessment. The aim of this
assessment is to examine higher cortical functions (attention, orien-
tation, memory, language, praxis, and executive function) from
patient narrative, collateral information from families, clinical exami-
nation, and standardized tests of cognitive function.30 For assess-
ment of cognitive impairment, a combination of tools and methods
are used (Table 3).
During the assessment, particular attention needs to be paid to
aspects such as vagueness with dates and events, repetition, inap-
propriate, or fixed ideas. A collateral account from a caregiver can
provide clarification of symptoms and their duration. Specific areas
requiring attention include features of depression, neurological or
psychiatric diseases, drug/medication use, uncorrected visual and
hearing problems, infections, cardiac/respiratory/renal failure, or fast
AF, all of which potentially affect cognitive function. Investigations
include complete blood count, blood glucose, creatinine, electrolytes,
calcium, liver and thyroid function tests, serum folate, and B12 levels.
Syphilis serology should be checked in high-risk patients. Magnetic
resonance imaging can be helpful to estimate cerebrovascular and
degenerative disease load and exclude tumours or normal pressure
hydrocephalus.
A list of cognitive assessment tools is provided in Table 4. Sev-
eral tools are available for cognitive assessment, but there is no con-
sensus on a preferred approach. The choice of tool should vary with
the purpose of testing and other factors, such as availability,
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familiarity, and feasibility.31 Common assessment tools are the two-
step general practitioner assessment of cognition (GPCOG) and the
Informant Questionnaire for Cognitive Decline in the Elderly
(IQCODE), both of which have been validated in large popula-
tions.32–34 Standardized assessment tools are not diagnostic instru-
ments and results need to be interpreted in the context of all
available evidence.
4 | ROLE OF IMAGING
Brain imaging studies can identify vascular disease as a cause of
dementia. In an autopsy study of patients with dementia, patho-
logic diagnoses implicated vascular disease in about 25% of sub-
jects, half of whom had pure vascular disease.52 The three main
causes of vascular cognitive impairment are large vessel strokes,
small vessel disease (SVD), and micro-haemorrhages. The preferred
imaging modality, magnetic resonance imaging (MRI), has high
specificity and sensitivity for detecting these changes and is an
important adjunct to clinical and psychometric assessments.
TABLE 2 Selected risk factors for dementia
Comments
Non-modifiable risk factors
Demographic factors
Age Dementia prevalence increases exponentially with age8
Sex Dementia prevalence greater in women than men7
Ethnicity VaD risk greater in blacks than whites9
Genetic factors Genetic alterations may affect cognitive function, e.g. apolipoprotein E e4 allele and ABCA7 are
associated with increased risk of AD; C9ORF72, MAPT, GRN gene mutations associated with
frontotemporal dementia; rs12007229 is associated with VaD10
Lifestyle factors
Education Lower education is associated with higher VaD risk11
Physical activity Increased physical activity is associated with lower risk of general dementia, Alzheimer’s dementia, and
VaD risk, which was attenuated with further adjustment for baseline cognitive, psychosocial, and vascular
factors. Review reported that seven out of eight studies found an association between increased physical
activity and lower risk of cognitive decline12
Body mass index U-shaped association between body mass index and dementia, with dementia risk higher in individuals who
were obese or underweight13
Smoking Meta-analysis reported that current smokers have higher risk of cognitive decline and dementia over
follow-up, than non-smokers or former smokers14
Social support and networks Compared with small social networks, larger social networks were associated with a lower risk of incident
dementia over time.15
Cardiovascular risk factors
Blood pressure Higher mid-life blood pressure was associated with higher dementia risk16 and cognitive decline17
Blood glucose Diabetes was associated with increased dementia risk18 and cognitive decline19
Lipids Higher total serum cholesterol was associated with higher VaD and AD risk20,21
Clinical cardiovascular or cerebrovascular disease
Stroke Stroke is associated with increased dementia risk22,23
AF AF is associated with increased dementia risk24,25
Vascular/peripheral arterial disease Carotid arterial disease is associated with incident dementia risk and cognitive decline26,27 Lower ankle
brachial index is associated with increased dementia risk28
Sleep apnoea Sleep-disordered breathing is associated with an increased risk of cognitive impairment and a small
worsening in executive function.29
ABCA7, ATP-binding cassette transporter A7; AD, Alzheimer’s disease; AF, atrial fibrillation; C9ORF72, chromosome 9 open reading frame 72; GRN,
granulin; MAPT, microtubule-associated protein tau; VaD, vascular dementia.
TABLE 3 Assessment of cognitive impairment
Suspect Patient history, appearance, changes in behaviour
Confirm Collateral history from family
Examine Full medical examination, brief screening assessment
Investigate Renal/liver/respiratory/thyroid compromise, B12, folate;
syphilis serology (in high-risk patients)
Exclude Depression, neurological/psychiatric disease,
medication/drug use
Measure Psychometric testing using validated battery
Image Multimodal MRI (T1, T2, T2*, DWI) for brain changes
Establish Diagnosis based on clinical + psychometric + imaging
DWI, diffusion-weighted imaging; MRI, magnetic resonance imaging.
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However, imaging findings need to be interpreted in the clinical
context because of uncertain correlation with symptoms or psy-
chometric test performance.53
Structural imaging is undertaken using T1- and T2-weighted spin
echo sequences to identify infarcts and macro-haemorrhages, T2*-
weighted gradient echo sequences for micro-haemorrhages, fluid-
attenuated inversion recovery imaging for incomplete infarcts and
leukoaraiosis and diffusion-weighted imaging (DWI) for visualising
the integrity of functional network fibre tracts not captured by other
imaging techniques. Magnetic resonance imaging provides several
markers of micro- and macrostructural organization that are sensitive
to change, related to clinical endpoints and has the potential to pre-
dict cognitive trajectories in individual patients.53
Magnetic resonance imaging signs that predict potential cognitive
impairments include (i) large or bilateral infarcts due to large vessel dis-
ease; (ii) strategic infarcts secondary to embolization in regions as hip-
pocampus, dominant thalamus, medial temporal, and deep frontal; (iii)
lacunes, white matter hyperintensities (leukoaraiosis) and haemor-
rhages associated with SVD; and (iv) lobar micro-haemorrhages repre-
sentative of amyloid angiopathies. In addition, although global cerebral
atrophy and/or medial-temporal lobe atrophy may suggest an element
of Alzheimer’s disease (mixed cognitive impairment), subcortical
infarcts, per se, may trigger progressive focal thinning and grey matter
atrophy in connected temporal and frontal cortical areas.31
Imaging of cerebral blood flow using arterial spin labelling, meta-
bolic imaging with proton magnetic resonance spectroscopy and
dynamic contrast-enhanced MRI can help estimate the extent of
injury, vessel permeability, and inflammation. Although these can dif-
ferentiate between dementias and separate pathological changes
from those due to aging, they remain research techniques with lim-
ited clinical application.
Positron emission tomography scans have also been used to
assess brain metabolic function, inflammation, amyloid or tau protein,
which may be helpful in differentiating some types of dementia.53
An overview of commonly used imaging modalities in cognitive
impairment is provided in Table 5.
5 | ATRIAL FIBRILLATION AND COGNITIVE
FUNCTION
5.1 | Atrial fibrillation, overt stroke, and cognitive
function
Evidence suggests that AF is associated with a higher risk for cogni-
tive impairment and dementia, with or without a history of clinical
stroke. Two meta-analyses that included both cross-sectional and
prospective studies specifically examined the incidence of dementia
in patients with AF and strokes.24,25 These meta-analyses found sim-
ilar estimates of the risk ratios of cognitive impairment or dementia
of 2.4324 and 2.7025 (Table 6).
It is uncertain whether or not the risk of cognitive impairment
and dementia varies in paroxysmal compared with persistent AF.
Many of the studies examining AF type were small and underpow-
ered and the factors that impact progression, such as rhythm control
approaches and physician approach to the patient management, can
introduce study biases. In a small hypothesis generating cross-sec-
tional study from the Atherosclerosis Risk in Communities (ARIC)
Cohort55 persistent but not paroxysmal AF classified by ambulatory
TABLE 5 Commonly used brain imaging modalities in cognitive impairment
Modality Use
CT Large infarcts/haemorrhage, established small vessel disease, other pathologies, limited application
MRI Imaging of choice for assessment of cognitive impairment54
T1 and T2 MRI Highly sensitive to old and new infarcts, estimation of white matter disease load, other pathologies (e.g. malignancies,
cerebral oedema)
T2* MRI Blood and blood products (e.g. haemorrhages), micro-haemorrhages, haemosiderin deposition, amyloid angiopathies
DWI MRI Extremely sensitive to early ischaemic changes (recent infarcts including micro-infarcts), integrity of fibre tracts, extensively
used for tractography assessing the structural integrity of connecting white matter tracts
1H-MRS Measurement of neuronal damage, inflammation, gliosis, differentiation between pathology and normal aging
1H-MRS, proton magnetic resonance spectroscopy; CT, computed tomography; DWI, diffusion-weighted imaging; MRI, magnetic resonance imaging.
TABLE 6 Meta-analyses relating atrial fibrillation to dementia and cognitive impairment
Author Study design Outcome Inclusions/exclusions Risk
Kwok et al24 Meta-analysis cross-sectional
and prospective studies
Dementia Patients with H/o stroke, 7
studies; n = 2425
OR 2.43; 95% CI: 1.70-3.46;
P < .001; I2 = 10%
Kalantarian et al25 Meta-analysis cross-sectional
and prospective studies
Cognitive impairment
and dementia
Patients with H/o stroke, 7
studies; n = 2409
RR 2.70; 95% CI: 1.82-4.00;
I2 = 32.3%; P = .18
Excluding patients with or adjusting
for H/o stroke 10 studies
RR 1.34; 95% CI: 1.13-1.5
H/o, history of; OR, odds ratio; RR, relative risk.
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telemetry monitoring was associated with lower cognitive function.
Another small cross-sectional study reported that cognitive perfor-
mance did not significantly differ by AF burden, but the number of
subclinical cerebral ischaemia areas was higher in individuals with
persistent compared with paroxysmal AF.56 More conclusive under-
standing of the relation of AF burden to cognitive decline and
dementia will require larger and longitudinal studies. The relation
between AF type and cognitive impairment and dementia is further
complicated by the sometimes arbitrary definition of the AF type in
the individual patient.
Unfortunately there are no randomized data examining the effi-
cacy of therapies and in particular of individualized management to
prevent dementia in individuals with AF.57 Of interest, the Fram-
ingham Heart Study has examined temporal trends in the incidence
of dementia and noted that the risk of dementia associated with
AF declined over three decades (1970s to the early 2010s).58 One
speculation is that improved anticoagulation and treatment of risk
factors were responsible for the declining incidence of dementia in
individuals with AF. Another piece of inferential evidence, support-
ing the benefit of preventing stroke as a strategy to prevent
dementia in individuals with AF, are observational meta-analyses
(Table 6). In individuals with AF but without stroke at baseline the
risk of dementia and cognitive decline is more modest [relative risk
(RR) 1.37, 95% confidence interval (CI) 1.08-1.73] than in individu-
als with both AF and a history of stroke (RR 2.7, 95% CI: 1.82-
4.00).25
Systemic anticoagulation remains the cornerstone of stroke pre-
vention treatment. By meta-analysis, adjusted-dose warfarin is asso-
ciated with a 64% (95% CI: 49-74%) significantly lower risk of stroke
(Table 7), whereas aspirin alone was associated with a 19% (95% CI:
1 to 35%) non-significant lower stroke risk.59 In studies comparing
warfarin and aspirin, warfarin was associated with a 38% (95% CI:
18-52%) stroke reduction, when compared with aspirin alone.59
A meta-analysis of the four randomized trials comparing the non-
vitamin K antagonist oral anticoagulants (NOACs) to warfarin,
demonstrated that the NOACs were associated with a significant risk
reduction (RR 0.81, 95% CI: 0.73-0.91) in overall stroke and systemic
emboli, in part driven by the significant risk reduction (RR 0.48, 95%
CI: 0.39-0.59) in haemorrhagic stroke.60
Since a prior stroke represents the strongest predictor of stroke
recurrence, all patients who have AF and have had an ischaemic
stroke should be anticoagulated, unless an absolute contraindication
exists.61 Of interest, a recent observational study using a propensity
score-matched analysis reported that in individuals with a history of
AF and dementia, persistent use of warfarin therapy was uncommon
(16%), but was associated with the prevention of stroke [hazard ratio
(HR) HR 0.74, 95% CI: 0.54-0.996; P = .047] and death (HR 0.72,
95% CI: 0.67-0.87; P < .001).62 A recent updated meta-analysis
reported a significant reduction of stroke, stroke or systemic embo-
lism, haemorrhagic stroke, and intracranial bleeding in AF patients
with previous stroke or transient ischaemic attack (TIA) receiving
NOACs compared with warfarin.63
5.2 | Atrial fibrillation, silent stroke, and cognitive
function
It is well established that AF increases the risk of clinical stroke by
four- to five-fold, and patients with a clinical history of stroke are at
increased risk of developing dementia.64–67 However, AF is also
associated with cognitive dysfunction ranging from mild impairment
to overt dementia, independently of clinical stroke as well as multi-
ple shared risk factors.64,67 It is also well established that AF and
TABLE 7 Meta-analyses examining anti-coagulation strategies in atrial fibrillation relating to stroke
Author Study design Outcome Inclusions/exclusions Risk
Hart et al59 Meta-analysis adjusted-dose
warfarin and aspirin
Stroke 6 RCTs warfarin vs placebo; n = 2900 RR 64% reduction, 95% CI: 49-74%;
Absolute reduction:
1° prevention 2.7% per year,
2° prevention 8.48% per year
7 RCTs aspirin vs. placebo
or no Rx; n = 3900
RR 19% reduction, 95% CI 1 to 35%;
1° prevention 0.8% per year,
2° prevention 2.5% per year
8 RCTs warfarin vs aspirin Rx;
n = 3647
RR 38% reduction, 95% CI: 18-52%;
1° prevention 0.7% per year,
2° prevention 7.0% per year
Ruff et al60 Meta-analysis
phase 3 RCTs:
Stroke and
systemic emboli
n = 29 312 NOAC; n = 29 272 warfarin RR 0.81, 95% CI: 0.73-0.91; P < .0001;
I2 = 47%; P = .13
n = 41 257, no prior stroke;
n = 17 269, prior stroke
RR 0.85, 95% CI: 0.72-1.01 RR 0.89;
95% CI: 0.77-1.02; Pinteraction = .30
RE-LY, ROCKET AF,
ARISTOTLE,
ENGAGE AF–TIMI 48
Ischaemic stroke n = 29 292 NOAC; n = 29 221 warfarin RR 0.92, 95% CI: 0.83-1.02; P = .10;
I2 = 32%; P = .22
Haemorrhagic
stroke
n = 29 292 NOAC; n = 29 221 warfarin RR 0.49, 95% CI: 0.38-0.64; P < .0001;
I2 = 34%; P = .21
H/o, history of; NOAC, non-vitamin K antagonist oral anticoagulant; RCT, randomized clinical trial; RR, relative risk.
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cognitive impairment share common risk factors, including advanced
age, diabetes, hypertension, sleep apnoea, and chronic heart failure.
Moreover, data have demonstrated a significant (34%) increase in
the risk of cognitive impairment in patients with AF in the absence
of clinical stroke, even after adjustment for shared risk factors.25,64
Thus, additional mechanisms beyond clinically recognized stroke and
shared risk factors may link AF and cognitive impairment. One of
the leading potential mechanisms is the occurrence of silent cerebral
infarcts, which occur significantly more frequently than clinical stroke
and are particularly common in patients with AF.68,69
Detection of cerebral ischaemic events on MRI is based on acute
hyperintense lesions on DWI. Brain MRIs reveal evidence of silent
cerebral infarcts in a significant percentage of patients with AF.69
The incidence is related to specifications of MRI and depends on the
definition applied.70 Atrial fibrillation is associated with a more than
two-fold increase in the risk of developing silent cerebral infarcts.69
Although silent infarcts are not associated with clinically apparent
acute neurologic deficits, data suggest a significant association
between silent infarcts and the development of cognitive decline
and dementia.56,71,72 Silent infarcts in patients with AF are believed
to be micro-embolic in origin and are identified as small, well-demar-
cated lesions, often in clusters, and are most prevalent in the frontal
lobes.56 The pattern of silent infarct distribution is similar to that
seen in vascular dementia, in which most silent strokes affect frontal
circuit components (frontal cortex, basal ganglia, and thalamus)
that play an important role in executive functioning.73 Thus, the term
“silent infarct” is probably a misnomer. Because of their small size
and location away from speech and motor centres, these micro-inju-
ries do not cause clinically apparent acute focal neurological deficits.
However, with the accumulation of silent infarcts and associated
repetitive brain injuries over time, micro-injuries may contribute to
the development of cognitive impairment. At least one study has
specifically addressed the role of subclinical cerebrovascular disease
as a mediator between AF and cognitive impairment. In a subset of
stroke-free participants in the ARIC study who underwent repeat
brain MRI after approximately 12 years, AF was associated with cog-
nitive decline only in those patients who had developed incident
silent cerebral infarcts.74
There is a paucity of evidence regarding the effect of anticoagu-
lation on silent cerebral infarcts and the risk of cognitive impairment.
One recent study addressed this issue by evaluating the time in ther-
apeutic range (TTR) as an indicator of the effectiveness of warfarin
anticoagulation in patients with AF. These investigators observed a
consistent increase in the risk of dementia as the percentage of TTR
decreased.75 The association between warfarin therapy and demen-
tia was “U”-shaped, with increased risk of dementia among patients
with overexposure and underexposure to warfarin [i.e. supra-thera-
peutic and sub-therapeutic international normalized ratios (INRs)].75
This may be due to cumulative brain injury from cerebral micro-
bleeds and silent infarcts, respectively. Recent observational data
also suggest that delaying warfarin therapy in patients with AF and
no history of dementia, including patients at low as well as high risk
for stroke, significantly increases the risk for developing incident
dementia.12,76 Whether the use of the NOACs will offer greater pro-
tection than warfarin in preventing AF-related cognitive impairment
and dementia remains to be determined. The significantly lower
intracranial haemorrhage and micro-haemorrhage rates,77 the lower
risk of mortality with intracranial haemorrhage with use of NOACs
compared with warfarin,78 coupled with comparable degrees of pro-
tection against thromboembolic stroke and substantially lower vari-
ability in therapeutic anticoagulation effect over time with NOACs,
offer reasons to hypothesize that these agents may be advantageous
to warfarin regarding protection against cognitive impairment in
patients with AF but this requires confirmation. Initial findings seem
to confirm this hypothesis.79
5.3 | Atrial fibrillation and cognitive function in the
absence of stroke
Longitudinal studies have shown that dementia is more common in
patients diagnosed with AF80,81 even in the absence of stroke. A
meta-analysis of eight prospective studies evaluating the relationship
between AF and incident dementia in patients without stroke and
baseline normal cognitive function included a total of 77 668
patients of whom 15% had AF. After a mean follow-up of about 8
years, 6.5% of patients developed dementia. Atrial fibrillation was
independently associated with increased risk of incident dementia
(HR 1.42, 95% CI: 1.17-1.72; P < .001).82 This result was confirmed
by a longitudinal analysis from the Cardiovascular Health Study
including 5150 participants without baseline history of stroke.83 Inci-
dent AF occurred in 11% of patients, with faster decline in mean
cognitive function scores, measured using the Modified Mini Mental
State Examination (3MSE), compared with patients in sinus rhythm.
Although both AF and dementia are diseases of aging, in two large
observational studies the highest RR of dementia was observed in
younger AF patients <70 years of age.84,85 A recent cross-sectional
study indicated that in individuals with heart failure with reduced
and preserved systolic ejection fraction, AF was associated with an
adjusted higher odds of presence and severity of prevalent cognitive
impairment.86 (≥80 years) the relationship between AF and dementia
seems to be mostly mediated by concomitant risk factors.87
The relationship between AF and cognitive decline may occur
through a variety of pathological mechanisms. Given the relationship
between AF and stroke, vascular dementia may be an obvious con-
tributor to cognitive decline, encompassing both multi-infarct
dementia and SVD dementia.80–83,88 The second form of dementia
in AF patients is Alzheimer’s disease, which is the most common
type of dementia overall. Atrial fibrillation has been identified as a
risk factor for Alzheimer’s disease.84,89 Alzheimer’s disease is the
result of accumulation of abnormally folded beta-amyloid and tau
proteins forming cerebral plaques which exert cytotoxic effects lead-
ing to cerebral atrophy. Interestingly, misfolded atrial natriuretic pep-
tides may lead to development of amyloid fibrils and deposits in the
atria of elderly patients with AF causing a specific atrial cardiomy-
opathy classified as EHRAS IVa.90,91 However, if AF and Alzheimer’s
disease share a common link with regards to protein misfolding and
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amyloidgenesis, it does not appear to be through the APOE e4
allele.92 Other studies suggest that the occurrence of Alzheimer’s
disease is related to hypoperfusion, inflammation, oxidative stress,
and endothelial dysfunction.93–95 All these factors may be induced
by several non-cardiac diseases resulting in an atrial cardiomyopathy
which in turn, leads to AF91 in the sense of both AF and Alzheimer’s
disease being the result of third confounding factors. Additionally,
several circulating biomarkers of oxidative stress, inflammation, and
endothelial dysfunction are elevated during AF.91,96,97 These factors
are also linked to cerebral SVD; therefore, AF may provide a specific
milieu for non-stroke related cognitive decline and dementia. For
example, hippocampal atrophy in AF patients may be mediated by
altered cerebral perfusion due to irregular R-R intervals, abnormal or
rapid heart rate, and reduced blood pressure caused by AF, since the
hippocampus is one of the most perfusion-sensitive structures of the
brain.94,98–101
Interestingly, patients with AF had lower total brain volume
when compared with those without AF, independent of cerebral
emboli in a large cross-sectional study.102 In addition, recently, AF
was associated with a decrease in total cerebral blood flow and brain
perfusion in an unselected elderly cohort.103 These results may, at
least in part, explain the association of AF with reduced relative
brain volume and cognitive impairment.
A schematic overview of the various mechanisms, through which
AF may lead to cognitive impairment is illustrated in Figure 1.
A number of trials are currently examining, as the primary or sec-
ondary outcome, the effect of different therapies including anticoagu-
lation and of different interventions on cognitive function in patients
with AF. A non-exhaustive list of such studies is found in Table 8.
The results of these studies will help to improve our understand-
ing of the relationship between AF and cognitive function and
provide us with more data for possible prevention of cognitive
decline by treatment of AF.
It should also be noted that, conversely, impairment of cognitive
function per se might have a negative impact on therapy adherence
and medication intake104,105 and might thus adversely affect treat-
ment effectiveness and outcome in patients with arrhythmias.
5.4 | Assessment of cognitive function in atrial
fibrillation patients in clinical practice
Despite increasing awareness about the relationship between AF
and cognitive decline,74,98,106,107 clinical guidelines for the manage-
ment of AF do not specifically include assessment of cognitive func-
tion in the diagnostic work-up. With increasing prevalence of
cognitive impairment in the elderly108 and given that the highest RR
of cognitive decline is in AF patients >70 years of age, healthcare
professionals who treat AF patients should be able to diagnose, and
assess risk factors for cognitive impairment appropriately.
Assessment of cognitive function should be multifaceted (see
Table 3), and psychometric testing is just one component. Numerous
validated tools are available to assess cognitive function, varying
from brief screening tools, which take 1-8 minutes to complete
among elderly patients, to more complex time-consuming neuropsy-
chological batteries (see Table 4). Brief screening tools may be most
applicable when cognitive impairment is suspected among AF
patients, whereas more comprehensive assessments may be per-
formed after appropriate referral to a geriatrician or neurologist.
Other factors determining the choice of test include the time avail-
able with the patient, the setting (office-based or inpatient), the
patient’s ability to speak English (some tools are not translated and/
or validated in other languages), and the purpose of the assessment
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(screening vs. confirmatory). In practical terms, any of the brief tests
could be used, although the most common is the GPCOG.42 In
research settings, the Mini Mental State Examination (MMSE) and
Montreal Cognitive Assessment (MOCA) have been commonly
used.43,44,109 Informant questionnaires, such as the second step of
GPCOG or the IQCODE,50 provide important additive information,
since they assess a patient’s change over time from someone who
knows the person well. This level of detail may not always be feasi-
ble, however, and may be more suited for comprehensive geriatric
or neurological assessment.
5.5 | Prevention of cognitive dysfunction in atrial
fibrillation patients
Since the precise mechanism(s) of cognitive disorders in patients
with AF is not fully known, the optimal way to prevent cognitive
dysfunction for a given patient remains to be established. Consid-
ering the mechanisms of cognitive impairment described in the
sections above, several therapies may be considered (see “Recom-
mendations”). Both disease states share common risk factors that
include aging, smoking, hypertension, diabetes, sleep apnoea, phys-
ical inactivity, vascular disease, inflammation, and heart failure.
Many of these risk factors represent modifiable targets for pre-
ventative therapies and if treated early may lower the risk of both
diseases.
Stroke prevention is the principal priority in the management of
AF and integrated approaches such as the Atrial fibrillation Better
Care (ABC) pathway (Avoid stroke, Better symptom management,
Cardiovascular and comorbidity risk reduction) may improve AF man-
agement.110 Stroke prevention therapy, particularly oral anticoagula-
tion, applied to the appropriate patients according to risk
stratification proposed in scientific guidelines107 may reduce the risk
of dementia. Fridberg and Rosenqvist111 studied 444 106 AF
patients over 1.5 million years at risk. Anticoagulation use was in
202 946 (46%) of the patients with the primary anticoagulant used
warfarin (94%). In AF patients not treated with anticoagulation, 60%
TABLE 8 Studies that are currently examining the effect of different therapies and interventions on cognitive function in patients with AF
or atrial tachyarrhythmias
Study name Target population Intervention Cognitive function as outcome
Impact of Anticoagulation Therapy on the
Cognitive Decline and Dementia in
Patients With Non-Valvular Atrial
Fibrillation (CAF), NCT03061006
Non-valvular AF Randomization to
dabigatran or warfarin
Primary outcome: incident dementia and
moderate decline in cognitive function
Comparison of Brain Perfusion in
Rhythm Control and Rate Control of
Persistent Atrial Fibrillation, NCT02633774
Persistent AF Randomization to rhythm
or rate control
Primary outcome: cognitive assessment
Cognitive Impairment Related to Atrial
Fibrillation Prevention Trial (GIRAF),
NCT01994265
AF patients >65 years old
and CHA2DS2-VASc >1
Randomization to
dabigatran or warfarin
Primary outcome: cognitive impairment
Early Treatment of Atrial Fibrillation
for Stroke Prevention Trial (EAST),
NCT01288352
AF patients Randomization to early
standardized rhythm
control or usual care
Secondary outcome: cognitive function
Apixaban During Atrial Fibrillation
Catheter Ablation: Comparison to
Vitamin K Antagonist Therapy (AXAFA),
NCT02227550
Patients undergoing catheter
ablation of non-valvular AF
Randomization to vitamin
K antagonists or apixaban
Secondary outcome: cognitive
function change
NOACs for Stroke Prevention in Patients
With Atrial Fibrillation and Previous ICH
(NASPAF-ICH), NCT02998905
Patients with a high-risk
of AF and previous
intracerebral haemorrhage
Randomization to non-
vitamin K antagonist oral
anticoagulant or
acetylsalicylic acid
Secondary outcome: cognitive function
Non-vitamin K Antagonist Oral
Anticoagulants in Patients With Atrial High
Rate Episodes (NOAH), NCT02618577
Patients with atrial high rate
episodes and at least two
stroke risk factors but
without AF
Randomization to edoxaban
or acetylsalicylic acid or
placebo
Secondary outcome: cognitive function
Optimal Anticoagulation for Higher Risk
Patients Post-Catheter Ablation for Atrial
Fibrillation Trial (OCEAN), NCT02168829
Patients having undergone
a successful AF catheter
ablation
Randomization to
rivaroxaban or
acetylsalicylic acid
Secondary outcome:
neuropsychological testing
Blinded Randomized Trial of
Anticoagulation to Prevent Ischaemic
Stroke and Neurocognitive Impairment
in AF (BRAIN-AF), NCT02387229
Patients with non-valvular
AF and with low risk of
stroke
Randomization to
rivaroxaban or
acetylsalicylic acid
Primary outcome: composite endpoint of
stroke, TIA and neurocognitive decline
Secondary outcomes: neurocognitive
decline, new onset of cognitive
impairment
AF, atrial fibrillation; NOACs, non-vitamin K antagonist oral anticoagulant; TIA, transient ischaemic attack.
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were on aspirin. In multivariate analysis, the strongest predictors of
dementia were in order: age (HR per decade 2.19, 95% CI: 2.16-
2.22), Parkinson’s disease (HR 2.46, 95% CI: 2.25-2.69), absence of
oral anticoagulation treatment (HR 2.08, 95% CI: 1.73-2.53), and
alcohol abuse (HR 1.53, 95% CI: 1.41-1.66).
In patients managed long term with vitamin K antagonists
(VKAs), for example, TTR is inversely associated with new-onset
dementia.75 Risk of dementia is augmented in AF patients who are
frequently over anticoagulated or receiving antiplatelet therapy.112
However, dementia can have a confounding effect on maintenance
of TTR, and oral anticoagulation in AF patients has not been con-
sistently associated with either improved cognitive function or less
hippocampal atrophy.98,109,113 Anticoagulation with warfarin neither
influenced the reduction of total brain volume nor cognitive func-
tion in individuals with AF.102 Non-vitamin K antagonist oral antico-
agulant therapy may reduce the incidence of brain micro-
haemorrhage compared with VKAs,60 but whether NOACs improve
long-term cognitive function is currently unknown. A recent com-
munity-based study provided some optimism in this regard and
found that NOAC therapies were associated with lower stroke and
dementia rates compared with warfarin.114 Considering the inci-
dence of dementia in AF, only trials with large numbers of patients
and extended long-term follow-up would be able to firmly establish
the possible benefit of oral anticoagulation on the subsequent risk
of cognitive decline.
Preventing early onset of AF through lifestyle or risk factor mod-
ification could delay the onset and progression of cognitive decline.
Prevention and early management of smoking, excess alcohol con-
sumption, hypertension, obesity, diabetes, and sleep apnoea may
reduce the onset and/or progression of AF115 with concomitant
reductions in stroke and possibly cognitive function. However, such
risk factor modifications may have independent positive effects on
cognitive function regardless of the development of AF. It is also
unclear if aggressive modification should start at the time of onset
of AF. Lifestyle modification may also reduce the risk of cognitive
decline in AF patients. Prevention of cognitive dysfunction may
include general measures proposed in the treatment and manage-
ment of vascular dementia or Alzheimer’s disease. Several trials have
tested the effects of physical activity and cognitive training in Alz-
heimer’s disease and have shown some evidence of efficacy on cog-
nitive endpoints.116 Most of the trials, however, had short follow-up
periods. Further evidence is needed to confirm the optimal design
and dose of interventions, the appropriate target population, and the
efficacy of such interventions. Innovations such as the development
of multi-domain interventions and the use of biomarkers or genetic
profiles to better target higher-risk patients are being assessed in
ongoing trials. However, differentiating the AF-dependent or AF-
independent effects of lifestyle and risk factor modifications remains
a major challenge.
There are no robust data to affirm that therapy for rhythm con-
trol with medication or “successful” AF catheter ablation can prevent
cognition disorders in AF patients. Atrial fibrillation catheter ablation
may not eliminate AF in the majority of patients, but rather
attenuate overall AF burden. Follow-up data beyond 5 or 10 years
are limited, and suggest that 2-5% of “successfully” ablated patients
will have recurrences annually.117–120 Furthermore, many of these
recurrences may be asymptomatic and the prognostic implication of
asymptomatic episodes on both stroke risk and cognitive function is
unknown.121–123 Catheter ablation as a specific therapeutic approach
to lower risk of stroke and dementia is discussed in the Catheter
Ablation section.
In patients with persistent AF for whom which rhythm control is
not pursued, atrioventricular (AV) node ablation with pacemaker
implantation that restores a predictable R-R interval and heart rate
has been shown, in a small study, to improve frontal and temporal
blood flow and improve memory and learning.124
Recommendations on the prevention of cognitive dysfunction in
AF patients are made in the Recommendations section. Most of
these recommendations are consistent with those of international
guidelines107 and are not necessarily unique to those patients with
AF and cognitive dysfunction.
6 | OTHER ARRHYTHMIAS AND
COGNITIVE DYSFUNCTION
6.1 | Cognitive dysfunction in patients with regular
supraventricular tachycardias
Recurrent supraventricular tachycardias in children and adolescents,
mediated by AV nodal re-entry or by accessory pathways, were
shown to be associated with cognitive deficits in 48% of such
patients, when assessed prior to catheter ablation.125 Whether an
early catheter ablation of supraventricular arrhythmia would affect
the cognitive status of such patients needs further investigation.
6.2 | Cognitive impairment after cardiac arrest
6.2.1 | Brain injury after non-fatal cardiac arrest
Cardiac arrest occurs in two different settings, in-hospital and out-
of-hospital, with completely different prognosis, for obvious reasons.
As cardiac arrests that occur in a hospital context are usually imme-
diately attended, the primary focus of the study of brain injury after
cardiac arrest has been among survivors of out-of-hospital cardiac
arrest (OHCA).126 In this setting, brain damage is caused by cerebral
hypoperfusion and its severity depends on the time of such defi-
cit127; the proportion of cardiac arrest survivors who present with
some degree of brain damage ranges from 35% to 100%.128,129 The
working group of Chun-Lim and colleagues has delineated three sce-
narios that are clearly related to the duration of brain hypoperfusion:
(i) patients with early recovery of brain function without any seque-
lae, usually associated with opportune resuscitation and/or early
recovery of consciousness (<3 days after OHCA); (ii) patients with
extensive damage, associated with prolonged coma (>7 days after
OHCA); and (iii) an intermediate group between those extremes.130
They report that a coma duration of <3 days results in a better
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quality of life at 3- and 12-month follow-up, and that the manifesta-
tion of severe cognitive impairment early on in recovery results in
higher risk for permanent memory and motor impairment.
Clinical sequelae of brain damage after OHCA may range from
mild memory impairment to severe physical and mental disability. As
expected, if brain damage persists, it negatively impacts patients’
quality of life.130,131 Cognitive impairment could include limited
attention span, personality disturbances, movement disorders (i.e.
Parkinsonism), and even dementia; however, memory seems to be
the cognitive function most affected in survivors of cardiac arrest.
Neuropsychological studies have shown deficits in different cognitive
areas including memory (64.3%), executive functioning (21.4%), lan-
guage (21.4%), and perception (14.3%).132 In 1990, the Utstein style
was developed in order to standardize the results of resuscitation
studies; this includes neurological evaluation using either the Cere-
bral Performance Category (CPC) or the Modified Rankin Scale
(mRS).133,134 Cerebral Performance Category classifies patients on a
scale from 1 to 5 (1 = good cerebral performance; 5 = deceased)
while the mRS classifies patients on a 0-6 scale (0 = asymptomatic;
6 = deceased); CPC scores of 1-2 and mRS scores of 0-3 are consid-
ered favourable neurological outcomes.134 These criteria are included
as a reminder of the risk of neurological dysfunction among sur-
vivors of cardiac arrest.
6.2.2 | Memory impairment after cardiac arrest
In patients successfully treated for an OHCA in a rapid emergency
response program, the long-term survival and quality of life are simi-
lar to age- and gender-matched controls.135 However, if cognitive
assessment is evaluated in detail, memory loss is prevalent.136
Alexander et al137 reported that among 30 selected patients (1 day
of coma, with responsiveness after 24 hours but with remaining con-
fusion for 7 days), only one-third of the sample suffered from motor
impairment after the event, but the total population showed at least
a mild degree of memory impairment. Torgersen et al138 also
reported that even after therapeutic hypothermia, 52% of the
patients who suffered cardiac arrest showed cognitive impairment,
especially episodic memory dysfunction. This finding is not new, in
1996, Grubb et al139 demonstrated in a population of 35 patients
that up to 37% of the patients suffered chronic memory impairment
after cardiac arrest, and that memory dysfunction was inversely pro-
portional to the duration of the event.
Memory impairment after cardiac arrest does not seem to
improve over time; a case-control study comparing OHCA patients
with patients who suffered acute coronary syndrome without OHCA
(controls) showed that memory impairment recorded at 3-month fol-
low-up remained unchanged after 12 months, with just mild
improvement of other functions.130 Further, only 16% returned to
work after the cardiac arrest whereas more than 94% of controls
returned to work.130 This study also evaluated quality of life among
cardiac arrest survivors and controls; physical quality of life was not
perceived as impaired in either group, however, the “cases” per-
ceived a worse quality of life as a result of memory impairment.130
6.2.3 | Therapeutic hypothermia to prevent
cognitive impairment after cardiac arrest
Although the effects of hypothermia have been evaluated in humans
and experimental models before,140,141 in 1956 Marchand and
Allan142 developed an experimental model to measure the effects of
hypothermia on the heart and brain. The first studies of therapeutic
hypothermia in cardiac arrest patients were performed in the 1950s.
Later, Zola-Morgan et al143 reported that ischaemic episodes dam-
aged CA1 hippocampal cells. The benefits of induced hypothermia
were demonstrated in animal models in the nineties.144 At the pre-
sent time, compelling evidence supports the use of targeted thera-
peutic hypothermia. Effectiveness of therapeutic hypothermia to
prevent cognitive impairment has been reported with varying results
among different authors.145 For example, Fugate et al145 followed
56 survivors of cardiac arrest treated with therapeutic hypothermia.
Twenty-month follow-up interviews yielded results favouring the use
of this therapy: 33 (60%) patients were reported as being “cogni-
tively normal”, with 79% of working patients returning to their nor-
mal activities after the event. In contrast, a randomized clinical trial
(RCT) of 70 patients comparing therapeutic hypothermia to a nor-
mothermic control group (without further intervention), found no
statistically significant difference in cognitive function between the
two groups, although the authors suggests that differences in the
neuropsychological tests employed (previous prospective studies
focusing on memory functions rather than executive functions) might
explain the neutral findings in this RCT.146 Current guidelines for
hospital care after cardiac arrest recommend the use of targeted
therapeutic hypothermia between 32 and 34°C for 48 hours.147
After publication of these guidelines, a systematic review by Sche-
none et al148 reported that mortality was halved [odds ratio
(OR) = 0.51, 95% CI: 0.4-0.64] and neurological impairment caused
by arrest-induced hypoxia was significantly lower (good neurological
outcome; OR = 2.48, 95% CI: 1.91-3.22) in patients who underwent
therapeutic hypothermia compared with those who did not.
In summary, minimising and treating the complications originating
from a cardiac arrest are almost as important as treating the arrest
itself. Physicians should perform appropriate follow-up and referral
to a specialized centre that can offer appropriate post-cardiac arrest
care in order to minimise the extent of brain damage and to avoid
adverse outcomes, since the ultimate success of medical therapy is
not only survival, but preservation of quality of life.
6.3 | Cardiac implantable electronic devices and
cognitive dysfunction
Patients requiring cardiac implantable electronic devices (CIEDs) are
generally older and as such may have associated cognitive dysfunc-
tion. It has also been shown that patients with severe bradycardia or
high-grade AV block may show impaired cognitive function.149–151
Bradycardia is also more common in patients treated for dementia
with cholinesterase inhibitor drugs (adjusted HR 1.4, 95% CI: 1.1-1.6)
and increases the risk of syncope, CIED need, and falls.152 A
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retrospective study showed that patients with cognitive dysfunction
were more likely than those without cognitive deficits to be implanted
with a pacemaker, even after adjusting for clinical risk factors.153
Treatment of both permanent or transient bradycardia with CIEDs has
been shown to improve cognition in a number of small trials.150,151,154
Although it may be inferred that patients with cognitive impair-
ment and standard device indications may be at increased risk for
device complications, this was not demonstrated in a study by Jama
et al155 However, the survival was lower than in matched controls
suggesting that these patients may have more co-morbidities. A
small study suggested that the increase in cerebral blood flow after
pacemaker implantation for symptomatic bradycardia resulted in
improvement in cognitive function.151 Another small study showed
that the improvement was, however, not significant over a 6-
12 months follow-up after pacemaker implantation.150 Ventricular
pacing may result in impaired haemodynamics and has been associ-
ated with AF, which itself has been associated with multi-infarct
dementia. Ventricular pacing was noted to show a trend towards a
detrimental effect on the visual memory score.156 It is well known
that CIED may have psychological side effects; this is particularly
true for ICD and especially shock therapy.157,158 Apart from this psy-
chological effect, there may be a direct effect on cognitive function.
Implantable cardioverter-defibrillator implantation with defibrillation
testing has been reported to initially result in cognitive dysfunction
in 31-39% of patients, as determined by neuropsychological testing
before and after ICD implantation in 52 patients, however most
patients improve within a year.159 Another study in 115 ICD patients
observed that cognitive function in memory was poor at baseline
and decreased over 12 months post-ICD implantation.160 In a small
Polish study of 51 patients with primary prevention ICDs, seven
patients who received ICD shocks for ventricular fibrillation scored
worse in neuropsychological measurements compared with patients
without such shocks, suggesting greater cognitive impairment,161
which could be multifactorial. However, further studies are needed
to demonstrate whether shock or prevention of ventricular fibrilla-
tion will prevent decline in cognitive function.
In contrast, there are several reports that cardiac resynchroniza-
tion therapy may be associated with neurocognitive functional
improvement.162–166 An early systematic review of three studies
reported improvements in executive functioning and attention.
6.4 | Catheter ablation
With mounting evidence to suggest an association between arrhyth-
mias and cognitive decline and dementia, treatment of these arrhyth-
mias has been considered as an option to lower risk of cognitive
decline. As antiarrhythmic drug therapies have variable efficacy and
are associated with many side effects, and medications can directly
influence quality of life, mood, and function,167 catheter ablation is
often employed as a durable non-pharmacological option.
The majority of evidence that catheter ablation may impact cog-
nition is derived from observational studies of AF management. Out-
comes in a consecutive series of 4212 patients who underwent AF
ablation were compared (1:4) with 16 848 age/gender-matched con-
trols with AF (no ablation) and 16 848 age/gender-matched controls
without AF. In this analysis, stroke outcomes of patients with AF,
and an ablation, were better than patients with AF and no ablation,
but similar to patients without AF.168 Similarly, long-term outcomes
of cognition were better in AF ablation patients compared with AF
patients who did not undergo ablation, including lower rates of Alz-
heimer’s, senile, and vascular dementia. Cognitive outcomes between
those patients that received an ablation were similar to patients
without a history of AF, including all subtypes of dementia. In
patients with atrial flutter stroke rates post-ablation are significantly
lower compared with AF patients treated with ablation.169 However,
as these were not RCTs, better outcomes could have been related
to selection bias rather than impact of ablation.
Dementia has not been a traditional endpoint in observational
studies of outcomes after AF ablation. However, stroke and TIA are
commonly reported endpoints. Long-term cognitive deficits are com-
mon after stroke with up to 10% of patients developing dementia
after their first stroke with an incidence that increases to 30-40%
with recurrent stroke.23 In a propensity-matched study of 969 con-
secutive AF ablation patients with a CHA2DS2-VASc score ≥2, AF
ablation was associated with a long-term reduced risk of stroke (HR
0.62, 95% CI: 0.47-0.82) and TIA (HR 0.47, 95% CI: 0.20-0.78).170 In
a separate observational study, AF ablation was associated with
lower rates of stroke/TIA compared with AF patients not treated
with ablation across all age and CHADS2 strata including patients
considered at high risk for stroke and patients with prior stroke.171
In this study, stroke rates in all groups increased with higher
CHADS2 scores, including non-AF patients, consistent with the influ-
ence of systemic risk factors on stroke risk beyond that of AF.
Catheter ablation of all arrhythmias has peri-procedural risks that
may have long-term significant consequences with regard to cogni-
tion and dementia risk. Procedural risk with all cardiac left sided pro-
cedures may impact long-term cognition due to the presence of
peri-procedural thrombus, atheroemboli, cerebral hypoperfusion,
sheath and wire manipulation and management, and anaesthesia. In
patients that undergo right sided cardiac procedures the risk is antic-
ipated to be lower although paradoxical thromboembolism can occur
in the presence of a septal defect.169 The risk of stroke during left
atrial catheter ablation is estimated at approximately 0.5-1%.121
However asymptomatic or subclinical ischaemic lesions develop in
up to 41% of AF ablation patients with an incidence that varies with
anticoagulation approach, ablation tool used, and cranial scan proto-
col.121,122,172,173 In addition, when peri-procedural transcranial Dop-
pler analysis is used during AF ablation to monitor for emboli, sheath
manipulation, removal and insertion of tools, and using of multiple
tools within the left atrium are significantly associated with micro-
embolic events.174 The risk of these lesions is higher (up to 63%)
during ventricular arrhythmia ablation with retro-aortic access and
long sheaths in the aorta being unique risk factors.175
To put these incidences in context with other cardiovascular pro-
cedures, the estimated incidence of new brain lesions has been
reported to be 8-18% after AF ablation, 11-17% after coronary
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angiography or percutaneous coronary intervention, 16-51% after
coronary artery bypass graft, 38-47% after surgical aortic valve
replacement, 68-91% after transaortic valve implantation, 4-34%
after carotid endarterectomy, 15-67% after carotid artery stenting,
11-20% after cerebral angiography, and 10-64% after endovascular
aneurysm procedures.176
The long-term consequences of asymptomatic or subclinical cere-
bral ischaemic events are unknown. It stands to reason that cranial
injury of any type, if persistent or accumulative can impact function.
However, cognition is not often tested serially after ablation and the
mechanisms that underlie the genesis of these cranial lesions are not
fully understood. In the prospective Mesh Ablator vs. Cryoballoon
Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrilla-
tion (MACPAF) study, high-resolution diffusion-weighted MRI imag-
ing, performed within 48 h after ablation, showed that new brain
lesions (range: 1-17) were present in 43.2% of patients.122 Follow-up
MRI at 6 months found that 12.5% of the acute brain lesions after
ablation formed a persistent scar. Neuropsychological assessment at
6 months found that there was not a significant consequence of
these lesions on attention or executive functions, short-term mem-
ory, or learning.122 However, other studies such as the ERACE study
reported much lower rates of permanent scar indicating the uncer-
tainty in this area.177
Based on the limited available data, post-AF ablation cognitive
dysfunction seems to be common. In a study of 150 patients who
underwent ablation, cognitive dysfunction was evident in 28% with
paroxysmal AF, 27% with persistent AF, 13% with supraventricular
tachycardia, and 0% in control patients with AF who did not
undergo ablation. Although these incidences decreased to 13%,
20%, and 3% at 90 days, measurable cognitive dysfunction per-
sisted; access time in the left atrium was the most significant proce-
dural variable of risk.123 Unfortunately in this study, MRI imaging
was not performed to determine and correlate this dysfunction with
peri-procedural cranial lesions. Neuropsychological outcomes were
sought at 3 months in a small study of 23 patients who underwent
ablation with post-procedure diffusion-weighted MRI cranial imag-
ing. New cranial lesions were detected in three (14%) patients and
one patient suffered a clinical stroke.161 Residual cognitive defects
were noted at 3 months with neuropsychological testing, in particu-
lar, in verbal memory (one of five cognitive domains); deterioration
was observed in 56.5% of ablation patients compared with 17.4% of
controls.178
6.5 | Implications for electrophysiological
procedures and cognitive function
As described in the preceding sections, emerging evidence suggests
that various electrophysiological procedures may be associated with
cerebral injury and the potential of cognitive decline therefore, it is
timely to consider current evidence and guidelines to minimise these
risks.
Over recent years considerable research has focused on how to
minimise these procedural risks during left sided catheter ablation
and in particular AF ablation. The routine use of transoesophageal
echocardiography (TOE) to identify pre-existing thrombus at the time
of AF ablation remains controversial particularly in an era where
most electrophysiological procedures will be performed on uninter-
rupted anti-coagulation. However, TOE studies have demonstrated
that up to 2% of anticoagulated AF patients may have left atrial
appendage thrombus or sludge with risk varying according to
CHA2DS2-VASc score. In the most recent AF ablation HRS/EHRA/
ECAS/APHRS/SOLAECE expert consensus statement guidelines,
51% of the writing group members perform a TOE in all patients
presenting for AF ablation regardless of presenting rhythm and anti-
coagulation status; 71% perform a TOE in patients presenting in AF
even on therapeutic anticoagulation, and 78% perform a TOE in
patients not previously anticoagulated even in sinus rhythm. Com-
puted tomography and intra-cardiac echocardiography have both
also been used to screen for thrombus but evidence from large com-
parative studies is lacking.
Evidence suggests that patients with an anticoagulation window
period or those requiring bridging are at increased risk of peri-proce-
dural events. Uninterrupted anticoagulation ensures the full antico-
agulant effect in the early post-procedural phase when embolic
events are most likely to occur.179,180 In this context, in recent years
it had become routine to perform AF ablation on uninterrupted war-
farin with a therapeutic INR. Until recently there were little data to
support this practice for NOACs however, emerging data from both
meta-analyses and a recent large randomized study support the
safety of this approach.179 This practice is likely to gain increasing
acceptance particularly as reversal agents become more widely avail-
able for all NOACs.
Intraprocedurally, a strategy of more aggressive heparin dosing
has evolved over the past decade in the light of data that patients
who have an activated clotting time (ACT) of <300 s during the pro-
cedure have an increased risk of silent cerebral infarction. The cur-
rent consensus document recommends an ACT target of 300-400
with repeated checks at 15-20 minutes intervals. In addition,
echocardiographic data have demonstrated that thrombus may form
on sheaths immediately following trans-septal puncture; as such 77%
of Consensus Document Writing Group181 members give heparin
prior to the trans-septal puncture.
Less data exist for ablation of ventricular arrhythmias although a
recent study demonstrated the presence of new silent cerebral
infarction in 7 of 12 patients having ablation of ventricular tachycar-
dia originating from the left ventricle. The majority of these patients
underwent ablation via a retrograde trans-aortic approach and the
target ACT was 300-400 seconds. Whether the incidence would be
lower using a trans-septal approach is unknown.
Similarly, limited data exist regarding the impact of device
implantation on cognitive function and these have been discussed in
the Cognitive Impairment after Cardiac Arrest section. Until more
comprehensive data are available it seems prudent to follow recom-
mendations in the 2015 HRS/EHRA/APHRS/SOLAECE expert con-
sensus statement on optimal ICD programming and testing even
though data that such an approach minimises cognitive impact are
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TABLE 9 Knowledge gaps and areas for further research
Knowledge gap(s) Further research
General dementia-related research domainsa
Distinguishing
progression of normal
aging from pre-clinical
cognitive decline
Physiology of normal
aging/pathological
neurodegenerative processes
• Large international population-based longitudinal studies of aging
and dementia
• Contribution of vascular conditions, inflammation, oxidative stress, and
the immune system to neurodegenerative processes causing dementia
Identification of the risk
factors and risk
reduction
Interactions of shared
pathological pathways
and risk factors
• Interactions of modifiable and non-modifiable dementia risk factors
in population-based studies
• Feasibility, administration and effectiveness of interventions
addressing dementia risk factors
Early diagnosis,
biomarkers and disease
monitoring
Effective strategies for
cognitive surveillance; Early
detection of cognitive
impairment; Monitoring
of disease progression
• Interventions for timely and accurate diagnosis of cognitive impairment
or dementia at the primary health-care level. Better characterization of
different dementia types
• Strategies for longitudinal surveillance of healthy individuals to
distinguish (and timely diagnose) pre-clinical neurodegenerative
diseases with cognitive impairment vs. normal aging
• Validation and standardization of available cerebrospinal fluid and brain
imaging biomarkers of dementia for research and clinical use
• Development and validation of novel biological, genetic, behavioural
or cognitive biomarkers with predictive value at pre-dementia stages
Prevention of cognitive
impairment/dementia
Effective preventive
strategies in general
population
• Exploring single- and multi-domain approaches for primary and
secondary prevention of dementia based on evidence on risk/protective factors and
the relationship with other chronic diseases
• Prevention studies need to start in mid-life and have a long follow-up
to identify “windows of opportunity” for effective interventions
Pharmacological and
non-pharmacological
clinical—translational
research on dementia
diagnosis and treatment
Effective dementia-specific
therapies are not available
yet
• Identification, validation and implementation of better defined outcome
measures for clinical trials of cognition, function and other biomarkers
of neurodegenerative diseases causing dementia
• Improvement in differentiation of dementia types
• Improvement in the selection of patients eligible for clinical trials of
cognitive impairment or dementia
• Investigation of combination therapies for dementia and diversification
of investigational therapeutic approaches (pharmacological and
non-pharmacological interventions)
AF-specific research domains
Association of AF with
cognitive impairment
or dementia
Underlying mechanisms
beyond clinically overt
strokes, silent strokes and
aging are poorly
understood
• Significance and contribution of cerebral hypoperfusion due to irregular
heart rhythm and impaired cardiac function in AF patients, AF-associated
hypercoagulability and OAC-related cerebral micro-bleeds to cognitive
deterioration and development of dementia
• Association of AF burden (i.e. paroxysmal vs non-paroxysmal AF) with
cognitive status
• Potential role of atrial cardiomyopathy in the development of
cognitive impairment/dementia
Time-course of cognitive
impairment in AF
patients
Mechanism(s) of accelerated
development of dementia
in AF patients
• Large prospective population-based studies on AF and non-AF patients
to identify the time-course of cognitive deterioration by AF status and
risk factors for accelerated dementia, thus providing a roadmap for
prevention strategies
• Identification and validation of clinical predictors and biomarkers to
identify AF patients at increased risk of cognitive impairment/dementia
Rhythm control and
other strategies,
including ablation, for
AF burden reduction
Short- and long-term effects
on cognitive function in
AF patients
• Better representation of elderly and other AF patients with, or at risk
for cognitive impairment or dementia in future rhythm control and AF
ablation studies
• Prospective investigation of the effects of rhythm control, AF ablation
and other strategies for AF burden reduction on cognitive function and
prevention, attenuation or delay of cognitive impairment/dementia
• Prospective investigation of the effects of different ablation energy
sources (e.g. radiofrequency, cryoablation) on cognitive function
(Continues)
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lacking. These include the 2A recommendation that: “It is reasonable
to omit defibrillation efficacy testing in patients undergoing initial
left pectoral transvenous ICD implantation procedures where
appropriate sensing, pacing, and impedance values are obtained with
fluoroscopically well-positioned right ventricular leads”; and the Class
3 recommendation that “Defibrillation efficacy testing at the time of
TABLE 9 (Continued)
Knowledge gap(s) Further research
Pharmacological rate
control therapies in AF;
AV node ablation with
permanent pacemaker
implantation for rate
control in AF
Short- and long-term effects
on cognitive function in AF
patients
• Prospective investigation of the effects of strict vs. lenient rate control
on cognitive function in AF patients including those with cognitive
impairment or dementia
• Better representation of elderly and other AF patients with, or at risk
for cognitive impairment or dementia in future prospective studies
investigating the effects of AV node ablation with permanent pacemaker
implantation on cognitive function and prevention, attenuation or delay
of cognitive impairment or dementia
VKA, NOACs and non-
pharmacological (LAAO)
thromboprophylaxis in AF
Long-term effects on
cognitive function in AF
patients
• Prospective studies of VKA, NOACs and LAAO long-term effects on
cognitive function in AF patients with baseline normal cognitive status,
cognitive impairment or dementia
• Assessment of benefits of VKA, NOACs for reduction of cognitive
decline among patients with micro-haemorrhages
• Identification and validation of clinical/biomarker predictors of cognitive
impairment/dementia in anticoagulated AF patients or those with LAAO
• Studies on the consequences of non-adherence or permanent OAC
discontinuation in AF patients with cognitive impairment or dementia
Screening for
asymptomatic AF
Asymptomatic AF-associated
risk of cognitive
impairment
• Assessment of cognitive impairment and dementia in patients with
asymptomatic AF
• Assessment of the effect of asymptomatic AF treatment on prevention,
attenuation or delay of cognitive impairment or dementia
Early AF detection
and treatment
Effects of early aggressive
rhythm control on cognitive
function
• Studies with pre-specified primary endpoint of cognitive function
• Inclusion of elderly and other AF patients with, or at risk for
cognitive impairment or dementia
Primary prevention of AF Effective interventions for
primary prevention
(ongoing research)
• Effects of dietary intervention, improved blood pressure control and
other risk factors control on cognitive function in patients at risk of
AF and cognitive impairment/dementia, and in non-AF patients with
cognitive impairment/dementia
Other arrhythmia-specific research domains
SCD risk assessment and
SCD prevention
Effective strategies in
individuals with cognitive
limitations
• Improvement of non-invasive risk assessment and identification of
screening tools applicable to older and other patients with, or at risk
for cognitive impairment or dementia
• SCD prevention studies to include cognitive function endpoints
Catheter ablation of
ventricular arrhythmias
Short and long-term effects
in individuals with cognitive
limitations
• Better understanding of the role of catheter ablation of ventricular
arrhythmias in older and other patients with, or at risk for cognitive
impairment/dementia, including studies of competing risk of death
caused by ventricular arrhythmias vs other causes
• Further studies on the impact of left sided and trans-septal vs.
trans-aortic access on cognitive function
ICD for primary and
secondary prevention
Short- and long-term effects
in patients with cognitive
limitations
• Studies on ICD implantation outcomes including procedural
complications, QALY gain, healthcare costs and competing risk of
death in patients with cognitive impairment or dementia
• Studies estimating life extension with ICD and end-of-life issues
in patients with cognitive impairment or dementia
• Further research on impact of antitachycardia pacing vs. defibrillation
on cognitive function
CRT Effects in patients with
cognitive limitations
• Studies of the impact of CRT, with or without ICD, on QoL and cognitive
function in patients with, or at risk for cognitive impairment or dementia
AF, atrial fibrillation; AV, atrioventricular; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; LAAO, left atrial appendage
occlusion; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulation; QALY, quality-adjusted life-years; QoL, quality of life; SCD,
sudden cardiac death; VKA, vitamin K antagonist.
aCompiled and modified from the Refs.131–133,185–187 (for details on the quality of care, delivery of care and services for individuals with dementia and
public awareness and understanding see the cited documents).
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implantation of a transvenous ICD should not be performed on
patients with a documented non-chronic cardiac thrombus, AF or
atrial flutter without adequate systemic anticoagulation, critical aortic
stenosis, unstable coronary artery disease, recent stroke or TIA,
haemodynamic instability, or other known morbidities associated
with poor outcomes”.
Regarding the impact of left atrial appendage occlusion (LAAO)
procedures on cognitive function, MRI-detected new acute brain
lesions were detected in 12 of 23 (52%) patients after LAAO proce-
dures using the Amulet, Occlutech, or LAmbre devices. New brain
lesions were associated with a higher number of left atrial appen-
dage angiographies although there was no apparent impact on cogni-
tive testing.182 Procedural stroke, typically related to air embolism,
has also been reported with the Watchman device in the PROTECT
trial, although impact on long-term cognition is unknown.183,184
However, any long-term impact on cognition has not been reported.
7 | CURRENT KNOWLEDGE GAPS, FUTURE
DIRECTIONS, AND AREAS FOR RESEARCH
Global management of dementia syndromes has been recently set as
a public health priority, and the World Health Organization has prior-
itized seven research domains to reduce the global burden of
dementia185: (i) Prevention, identification, and reduction of risk; (ii)
Quality of care for people with dementia and their carers; (iii) Deliv-
ery of care and services for people with dementia and their carers;
(iv) Diagnosis, biomarker development, and disease monitoring; (v)
Pharmacological and non-pharmacological clinical—translational
research; (vi) Public awareness and understanding; and (vii) Physiol-
ogy and progression of normal ageing and disease pathogenesis.
Other expert groups have also provided recommendations for fur-
ther progress and improvements in dementia-related research186 and
highlighted knowledge gaps in cardiovascular care of the elderly,
including those with cognitive impairment.187 Declining incidence
and age-specific prevalence of dementia in high-income coun-
tries188–191 implies that dementia risk is modifiable, likely through
improved management of cardiovascular risk factors192 and psy-
chosocial factors.186,193–195 Although dementia-prevention RCTs
failed to confirm many signals from observational studies, those
RCTs highlighted some key methodological issues to be considered
in contemporary trials (Table 9).
Elderly patients with cognitive impairment commonly have mixed
pathologies, including cardiovascular disease (e.g. AF and heart fail-
ure)80,85,196–198 but the complexity of shared pathological pathways
and risk factors is still poorly understood and warrants further
research. Better understanding of the mechanisms and determinants
of AF-related cognitive impairment/dementia beyond aging and
stroke would inform AF-specific preventive strategies to attenuate
and/or postpone cognitive deterioration. Prospective studies
addressing the long-term effects of AF treatments directed towards
rhythm control, reduction of total AF burden and improvement in
cardiac function (i.e. catheter ablation and pharmacotherapy) on
cognitive function are needed. Inherent to achieving these targets is
consistent utilization of well-validated neurocognitive measures.
Also, the effects of lifestyle changes resulting in weight loss,
improvement in overall cardio-metabolic risk profile and reduced AF
burden need to be investigated. Further research is needed to opti-
mise rate control in AF relative to cognitive function.
Cognitive endpoints were not addressed in the recent large RCTs
of OAC (oral anticoagulation: VKA or NOACs) for thromboprophy-
laxis in AF, with one exception, the Birmingham Atrial Fibrillation
Treatment of the Aged Study (BAFTA) which reported better cogni-
tive function in elderly patients receiving warfarin compared with
aspirin.113 In retrospective observational studies the risk of dementia
increased with poor management of VKA (a low TTR),75,112 whilst
NOAC use was associated with lower risk for dementia compared
with warfarin.114 Observational data on AF patients diagnosed with
dementia consistently shows significant VKA underuse or discontinu-
ation62 even post-stroke,199 despite similar VKA-related bleeding risk
irrespective of the cognitive status. Large prospective studies with
pre-specified cognitive outcomes are needed to identify optimal
thrombo-prophylactic strategies for AF patients with cognitive
TABLE 10 Interventions to be considered for prevention of
cognitive dysfunction in atrial fibrillation patients
Pharmacological interventions
In relation to AF management
Oral anticoagulation (early identification of appropriate candidates,
improving drug adherence, avoiding warfarin in those with poor
TTR, and optimal TTR management)
Rhythm control
Antihypertensive treatment
Treatment of concomitant heart failure
Non-specific pharmacological interventions:
Glycaemic control
Hormone replacement therapy
Avoid aspirin therapy unless specific clinical indication present
Alzheimer’s disease-specific pharmacological interventions
Multifactorial vascular risk factor management
Targeting blood pressure, cholesterol, diabetes, sleep apnoea,
obesity via diet, medication, smoking cessation, and physical
activity
Nutritional interventions
Low levels of vitamin D and B12, and folate increase risk, but the
value of supplementation remains unproven. Calcium
supplementation in women has been associated with increased
dementia risk.200–202 The value of modulating cognitive function
based on educational interventions is uncertain.
Weight loss in obesity203
Others
Cognitive activities or training
Physical exercise
Multi-domain interventions
AF, atrial fibrillation; TTR, time in therapeutic range.
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impairment/dementia. Importantly, the effects of early AF treatment
or primary AF prevention on cognitive deterioration in patients at
risk for both conditions remain to be elucidated.
Elderly patients and those with cognitive impairment/dementia
were generally under-represented in catheter ablation and CIED
(i.e. ICD and cardiac resynchronization therapy) trials. Studies are
needed to better define the risks and benefits of cardiac arrhyth-
mias ablation or CIED implantation, long-term effects of these
interventions on cognitive status and optimal strategies for shared
decision-making and end-of-life decisions in these patients
(Table 9).
8 | RECOMMENDATIONS
Interventions that can be considered for prevention of cognitive dys-
function in AF patients are summarized in Table 10. The writing
committee reached consensus on recommendations summarized in
Table 11.
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